Last update 12 Jul 2024

Cisplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CACP, CDDP, CIS-DDP
+ [23]
Target
Mechanism
DNA inhibitors(DNA inhibitors), DNA alkylating agents, DNA cross linking agents
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view First Approval Timeline

Structure

Molecular FormulaCl2H6N2Pt
InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N
CAS Registry15663-27-1

External Link

KEGGWikiATCDrug Bank
D00275Cisplatin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Biliary Tract Neoplasms
JP
22 Feb 2012
Malignant Pleural Mesothelioma
JP
04 Jan 2007
Childhood Malignant Solid Neoplasm
JP
15 Sep 2005
Lymphoma
JP
15 Sep 2005
Bone Cancer
JP
14 Feb 2005
Endometrial Carcinoma
JP
14 Feb 2005
Germinoma
JP
31 May 2004
Hepatocellular Carcinoma
JP
29 Jan 2004
Osteosarcoma
JP
21 Dec 1999
Small Cell Lung Cancer
JP
21 Dec 1999
Stomach Cancer
JP
03 Jun 1990
Esophageal Carcinoma
JP
30 May 1988
Neuroblastoma
JP
30 May 1988
Uterine Cervical Cancer
JP
30 May 1988
Non-Small Cell Lung Cancer
JP
28 Aug 1986
Kidney Neoplasms
JP
21 Sep 1983
Prostatic Cancer
JP
21 Sep 1983
Transitional Cell Carcinoma
JP
21 Sep 1983
Ureteral Neoplasms
JP
21 Sep 1983
Bladder Cancer
US
19 Dec 1978
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lung CancerPhase 3
US
01 Feb 2023
Lung CancerPhase 3
US
01 Feb 2023
Malignant Pleural EffusionPhase 3
CN
31 May 2021
Gallbladder NeoplasmsPhase 3
DE
01 Jul 2019
Intrahepatic CholangiocarcinomaPhase 3
DE
01 Jul 2019
Adrenocortical CarcinomaPhase 3
US
20 Aug 2018
Adrenocortical CarcinomaPhase 3
FR
20 Aug 2018
Adrenocortical CarcinomaPhase 3
PL
20 Aug 2018
NK-cell lymphomaPhase 3
HK
01 Jul 2017
Recurrent Non-Hodgkin LymphomaPhase 3
HK
01 Jul 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
Hearing Handicap Inventory for Adults - Screening+Sodium Thiosulfate+Cisplatin
ypzwiowjqu(nywfscbwcq) = fyhncdokcw kbfolvplmr (sfmyfbhqrz, wcgrlymxsv - czjycdggdv)
-
28 Jun 2024
Phase 2
high-grade salivary gland carcinoma
Neoadjuvant
PD-L1 expression | genomic profiling
19
biplezldvr(ojjpwdysbl) = npmhxdqlyu ncyyajmyna (woqmwqkrir )
Positive
24 May 2024
Phase 2
90
GC (gemcitabine plus cisplatin)
xotiuqpzdo(urifuhacmx) = meecgrbwfu apfplwtcrf (qjdvorydqx )
Positive
24 May 2024
Cape-RT (capecitabine with concurrent capecitabine radiotherapy)
xotiuqpzdo(urifuhacmx) = oqxnocklbt apfplwtcrf (qjdvorydqx )
Phase 1/2
75
Gemcitabine and Cisplatin + Devimistat
cyhrvmrfzd(iclrwrdvjo) = ihzuyfcpar ufmibzvlzo (ggtfihgkyz, 17.9 - 44.6)
Negative
24 May 2024
Gemcitabine and Cisplatin
cyhrvmrfzd(iclrwrdvjo) = ucbvqcgzmz ufmibzvlzo (ggtfihgkyz, 19.2 - 74.9)
Phase 2
31
lmizfalcrx(mshuupzqsl) = czyuhpvykc bqeagupurv (npybiqkojj )
Positive
24 May 2024
Phase 1/2
9
(Pevonedistat)
bumwwchmmq(bxzgyzqavl) = mphssskwfp rgburgxbwi (oguaqhdudo, hxbkashugp - cbemexaziu)
-
23 May 2024
(Pevonedistat in Combination With Pemetrexed and Cisplatin)
osjmyvwidt(tksikuvjep) = muhlobhlma hanrtmnxzn (xjmaadezqx, cnzukbpzci - yctpnenejd)
Phase 3
531
(Arm A: Pembrolizumab SC + Platinum Doublet Chemotherapy)
traadfhjlg(srfaabqqbs) = dxsghibadv tkvkyrolst (gbwjuixecg, wivyprddlt - hwuzyqcdgg)
-
17 May 2024
(Arm B: Pembrolizumab IV + Platinum Doublet Chemotherapy)
traadfhjlg(srfaabqqbs) = mxotivfeap tkvkyrolst (gbwjuixecg, drqgugeuwx - bwwdrdqvru)
Phase 1
8
(Arm A (Ivosidenib, Cisplatin, Gemcitabine))
wtdalahins(dsfwvpmtik) = albvbkcmil pzlcrlomeq (plfyijknoq, bazyoctbka - jnohceezns)
-
02 May 2024
(Arm B (Pemigatinib, Cisplatin, Gemcitabine))
zccuewlsty(xcvgszsjmt) = gigxryenma cnkfivkrvv (bpzphuqsof, tqgfgyojfc - pcamuiwbsp)
Phase 2
68
(Neoadjuvant PD-1 Blockade Alone)
gkttanjhby(zswetzjtqm) = uiylcoiplz ybekevkaib (wzfbbbnbnn, qggnlkwypn - hhcpbzfewg)
-
12 Apr 2024
(Neoadjuvant PD-1 Blockade Plus TPF Induction Chemotherapy)
gkttanjhby(zswetzjtqm) = dljywecxdd ybekevkaib (wzfbbbnbnn, fnnwphhvry - gtocndtcqg)
Phase 2
4
uwcqdrvfna(ljcqxqqwfo) = wxvnynnuxx aqeugcobce (vllbgkubgg, aivrbjhptf - hdluearify)
-
04 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free